These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 7809837)
21. Calcium-dependent release of N-terminal fragments and intact immunoreactive parathyroid hormone by human pathological parathyroid tissue in vitro. el-Hajj Fuleihan G; Chen CJ; Rivkees SA; Marynick SP; Stock J; Pallotta JA; Brown EM J Clin Endocrinol Metab; 1989 Oct; 69(4):860-7. PubMed ID: 2778039 [TBL] [Abstract][Full Text] [Related]
22. Relationship between parathyroid hormone secretion and cytosolic calcium concentration in dispersed bovine parathyroid cells. Shoback DM; Thatcher J; Leombruno R; Brown EM Proc Natl Acad Sci U S A; 1984 May; 81(10):3113-7. PubMed ID: 6328497 [TBL] [Abstract][Full Text] [Related]
23. Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Indridason OS; Heath H; Khosla S; Yohay DA; Quarles LD Kidney Int; 1996 Nov; 50(5):1663-71. PubMed ID: 8914034 [TBL] [Abstract][Full Text] [Related]
24. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Intravenous Pamidronate for Parathyroid Hormone-dependent Hypercalcemia in Hospitalized Patients. Rosenblum RC; Twito O; Barzilay-Yoseph L; Ramaty E; Klein N; Rotman-Pikielny P J Clin Endocrinol Metab; 2021 Oct; 106(11):e4593-e4602. PubMed ID: 34157125 [TBL] [Abstract][Full Text] [Related]
26. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism. Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416 [TBL] [Abstract][Full Text] [Related]
27. Decrease of serum calcium concentration and lost influence of calcium on parathyroid hormone release in a patient with primary hyperparathyroidism after treatment with diphosphonates. Kotzmann H; Bernecker P; Svoboda T; Niederle B; Luger A Calcif Tissue Int; 1993 Nov; 53(5):301-3. PubMed ID: 8287315 [TBL] [Abstract][Full Text] [Related]
28. Reversibility of experimental secondary hyperparathyroidism. Lewin E; Wang W; Olgaard K Kidney Int; 1997 Nov; 52(5):1232-41. PubMed ID: 9350646 [TBL] [Abstract][Full Text] [Related]
29. Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism. Jansson S; Morgan E World J Surg; 2004 Dec; 28(12):1293-7. PubMed ID: 15517486 [TBL] [Abstract][Full Text] [Related]
30. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. Lerner UH; Larsson A Bone; 1987; 8(3):179-89. PubMed ID: 2955802 [TBL] [Abstract][Full Text] [Related]
31. Parathyroid expression of calcium-sensing receptor protein and in vivo parathyroid hormone-Ca(2+) set-point in patients with primary hyperparathyroidism. Cetani F; Picone A; Cerrai P; Vignali E; Borsari S; Pardi E; Viacava P; Naccarato AG; Miccoli P; Kifor O; Brown EM; Pinchera A; Marcocci C J Clin Endocrinol Metab; 2000 Dec; 85(12):4789-94. PubMed ID: 11134144 [TBL] [Abstract][Full Text] [Related]
32. Endothelin-induced calcium signaling and secretion in chief cells and fibroblasts from pathological human parathyroid glands. Ridefelt P; Hellman P; Carling T; Rastad J; Akerström G Recept Signal Transduct; 1997; 7(4):269-78. PubMed ID: 9633827 [TBL] [Abstract][Full Text] [Related]
33. Different secretory actions of pancreastatin in bovine and human parathyroid cells. Ridefelt P; Hellman P; Stridsberg M; Akerström G; Rastad J Biosci Rep; 1994 Oct; 14(5):221-9. PubMed ID: 7772715 [TBL] [Abstract][Full Text] [Related]
34. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. Kifor O; Moore FD; Wang P; Goldstein M; Vassilev P; Kifor I; Hebert SC; Brown EM J Clin Endocrinol Metab; 1996 Apr; 81(4):1598-606. PubMed ID: 8636374 [TBL] [Abstract][Full Text] [Related]
35. Hyperphosphatemia modestly retards parathyroid hormone suppression during calcitriol-induced hypercalcemia in normal and azotemic rats. Jara A; Chacón C; Felsenfeld AJ Nephron; 2002 Dec; 92(4):883-8. PubMed ID: 12399635 [TBL] [Abstract][Full Text] [Related]
36. Effects of gallium nitrate on calcium transients in UMR-106 rat osteoblastic osteosarcoma cells. Lakatos P; Tatrai A; Stern PH Bone; 1992; 13(5):379-86. PubMed ID: 1419379 [TBL] [Abstract][Full Text] [Related]
37. Calcium-sensing receptor gene polymorphism affects the parathyroid response to moderate hypercalcemic suppression in patients with end-stage renal disease. Yokoyama K; Shigematsu T; Tsukada T; Hara S; Yamada A; Kawaguchi Y; Hosoya T Clin Nephrol; 2002 Feb; 57(2):131-5. PubMed ID: 11863123 [TBL] [Abstract][Full Text] [Related]
38. Neomycin interacts with Ca2+ sensing of normal and adenomatous parathyroid cells. Ridefelt P; Hellman P; Wallfelt C; Akerström G; Rastad J; Gylfe E Mol Cell Endocrinol; 1992 Feb; 83(2-3):211-8. PubMed ID: 1547911 [TBL] [Abstract][Full Text] [Related]
39. [Disodium pamidronate (APD) in therapy of hypercalcemia in primary hyperparathyroidism]. Kotzmann H; Svoboda T; Bernecker P; Clodi M; Woloszczuk W; Niederle B; Waldhäusl W; Luger A Wien Klin Wochenschr; 1994; 106(13):422-5. PubMed ID: 8091766 [TBL] [Abstract][Full Text] [Related]
40. Fluoride interactions with stimulus-secretion coupling of normal and pathological parathyroid cells. Ridefelt P; Hellman P; Rastad J; Larsson R; Akerström G; Gylfe E Acta Physiol Scand; 1992 Jul; 145(3):275-85. PubMed ID: 1325732 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]